Federal Right-to-Try Legislation — Threatening the FDA’s Public Health Mission

NEJM, 10 January 2018
Authors: Steven Joffe, Holly Fernandez Lynch
“Though popular with the public and supported by politicians from both parties, the legislation has been widely criticized by policy experts. In isolation, its impact would probably be limited, since the bill was substantially hollowed out to secure the necessary votes. Nonetheless, the motivation behind the proposed legislation threatens to weaken the FDA’s ability to pursue its public health mission.”
Find article here.

Makers of Nurofen ran ‘misleading and deceptive’ campaign against Panadol: court

SMH, 11 January 2018
Author: Stephanie Gardiner
“Nurofen is better than paracetamol for common headaches,” declared the advertisements in women’s lifestyle magazines. The Federal Court has found that claim to be misleading and deceptive, after two pharmaceutical giants went head-to-head in a two-year legal battle.”
Find article here.

The Nuremberg Code and Informed Consent for Research

JAMA. 2018; 319(1): 85-86
Author: Jon F Merz
“The Viewpoint by Dr Moreno and colleagues understated the precedential value of the International Medical Tribunal’s decision in the trial of Nazi doctors accused of war crimes that established the Nuremberg Code and the code’s influence on common law development of the legal duty of researchers to secure informed consent from their research participants.”
Find letter here.